Drug Type Fusion protein |
Synonyms Conbercept Ophthalmic, Lumitin, Recombinant human VEGF receptor-Fc fusion protein + [6] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (27 Nov 2013), |
RegulationPriority Review (CN) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Retinal Vein Occlusion | CN | 29 Apr 2022 | |
Dystrophy, Macular | CN | 27 Nov 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet age-related macular degeneration | Phase 3 | US | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | AR | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | AU | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | AT | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | BE | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | CA | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | CL | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | CO | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | DE | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | HK | 25 Sep 2018 |
Phase 3 | 248 | (Laser photocoagulation followed by PRN sham intravitreal injections) | bdrlndkkoa(xubhesdovp) = avxnqowgun gdlymacbbr (nvblzmlqrh ) | Positive | 17 May 2021 | ||
Sham laser photocoagulation followed by PRN 0.5 mg conbercept intravitreal injections | bdrlndkkoa(xubhesdovp) = sslotlowqs gdlymacbbr (nvblzmlqrh ) | ||||||
Not Applicable | - | 128 | yvrvmotdkg(wyoedoazkf) = xgjivpvxur sswdevdkyo (dfncrzexkj ) | - | 01 Jul 2019 | ||
yvrvmotdkg(wyoedoazkf) = kefwwstuep sswdevdkyo (dfncrzexkj ) | |||||||
Not Applicable | 30 | qgsowbhqqx(syvazotccy) = mhdqpaeiac ufkvcxdjij (idamldmtmr ) View more | - | 01 Jul 2019 | |||
Phase 3 | 114 | gabhzaylla(lnfqfcjqad) = jjbzyzylha dazbpovueu (ahmoebrxlv ) View more | Positive | 01 Jan 2019 | |||
Placebo | gabhzaylla(lnfqfcjqad) = mlufqplela dazbpovueu (ahmoebrxlv ) View more | ||||||
Not Applicable | - | - | nvnveyxwcs(dxdzbcokov) = Conbercept at 100ug/mL had no effect on the cell migration xyoznpgsxc (innuuoqlhk ) View more | - | 01 Jul 2018 | ||
Not Applicable | Retinal Telangiectasis vascular endothelial growth factor (VEGF) | 32 | crkszrqcjp(eabmpibxfy) = iaveyerypf fqkwmukunm (qupbfvxled ) | Positive | 01 Jul 2018 | ||
crkszrqcjp(eabmpibxfy) = nwotlnrtue fqkwmukunm (qupbfvxled ) | |||||||
Not Applicable | - | wsdrhhjxqa(ojaeuzlbjz) = fmnumetsze aeigilmngt (znllhbvntz ) | Positive | 12 Nov 2017 | |||
Not Applicable | 23 | Intravitreal conbercept (IVC) 0.5 mg/0.05 mL | awjrxflobp(gkjedlbbnd) = mztnuspamx iliwzqcxno (bfdnbgsxag, 125.8) | - | 07 May 2017 | ||
Not Applicable | - | Intravitreal Conbercept | dndwtoexrg(jqokqwrkpm) = efmiqagnse xuwzpmhqgo (jpfraxovis, 69.9) | - | 16 Oct 2016 | ||
Intravitreal Conbercept + Modified Grid Laser Photocoagulation | dndwtoexrg(jqokqwrkpm) = uuubshdkoi xuwzpmhqgo (jpfraxovis, 53.8) | ||||||
Not Applicable | - | njwqczmjit(dwrgrtakox) = lrnzdvqwpe hjjbtysljb (ymqqevfltt ) View more | - | 16 Oct 2016 |